Geneoscopy’s ColoSense Medicare win puts stool RNA testing into the colorectal screening mainstream
Medicare coverage gives ColoSense a bigger test: can stool RNA screening move from FDA approval to real colorectal cancer adoption?
Why Tempus’ tumor-only xT CDx approval could matter for precision oncology testing
Find out how Tempus’ tumor-only xT CDx FDA approval could expand precision oncology testing and reshape solid tumor profiling.
Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
KRAS G12D was long seen as nearly untouchable. Ranok’s RNK08954 now has early clinical data, but the pivotal test is still ahead.
Can KLEOS change how colorectal cancer trials are run for patients with limited treatment options?
CRC trials need faster evidence. KLEOS could test more therapies under one platform. Read why the model matters.
Can Brenus Pharma crack the cold-tumor problem in metastatic colorectal cancer?
Find out how Brenus Pharma’s STC-1010 FDA IND acceptance could reshape MSS colorectal cancer immunotherapy development.
Why Cartography Biosciences’ Phase 1 colorectal cancer trial matters after Samsung Ventures backing
Samsung wants oncology optionality beyond manufacturing. Cartography’s Phase 1 T-cell engager puts platform biology under pressure.
Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.
CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.
Is botensilimab finally ready for a bigger melanoma spotlight? Agenus bets on ASCO 2026
Agenus will unveil first Phase 2 botensilimab melanoma data at ASCO 2026. Read why the update could reshape sentiment around its checkpoint platform.
Can Mabwell’s ADC 7MW4911 overcome drug resistance in late-stage GI cancers?
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
Pfizer’s BRAFTOVI triplet shows 64% response in first-line BRAF-mutant colorectal cancer
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.